Page last updated: 2024-08-23

raloxifene hydrochloride and Hip Fractures

raloxifene hydrochloride has been researched along with Hip Fractures in 30 studies

Research

Studies (30)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	1 (3.33)	18.2507
2000's	19 (63.33)	29.6817
2010's	9 (30.00)	24.3611
2020's	1 (3.33)	2.80

Authors

Authors	Studies
Chen, CY; Hwang, SJ; Lee, TC; Lin, MY; Lin, SJ; Lin, YC	1
Silverman, S	1
Bouvet, A; Caruba, T; Pouchot, J; Sabatier, B; Savoldelli, V	1
Reid, IR	1
Abrahamsen, B; Eiken, P; Roerholt, C	1
Oshima, H; Tanaka, I	1
Ito, M	1
Brookhart, MA; Cadarette, SM; Katz, JN; Patrick, AR; Solomon, DH	1
Cochet, T; Cohade, C; Pouillès, JM; Ribot, C; Trémollieres, F	1
Mosekilde, L; Rejnmark, L; Schwartz, F; Vestergaard, P	1
Ferrari, S; Fujiwara, S; Hagino, H; Lange, JL; Nakamura, T; Watts, NB	1
Iba, K; Takada, J; Yamashita, T	1
Briongos, L; Dueñas-Laita, A; García-Alonso, M; Pérez-Castrillón, JL; Ruiz-Mambrilla, M; Sañudo, S	1
Flik, KR; Gardner, MJ; Lane, JM; Mooar, P	1
Broy, SB; Derosa, AM; Harrington, JT; Licata, AA; Shewmon, DA	1
Begerow, B; Minne, HW; Pfeifer, M; Pollähne, W	1
Barrett-Connor, E; Cauley, JA; Cox, DA; Geiger, MJ; Kulkarni, PM; Sashegyi, A	1
Delmas, PD; Kulkarni, PM; Plouffe, L; Silverman, SL; Stock, JL; Wong, M	1
Brecht, JG; Huppertz, E; Kruse, HP; Möhrke, W; Oestreich, A	1
Shintani, M	1
Bartl, R	1
Gluck, O; Maricic, M	1
Brown, SA; Rosen, CJ	1
Chesnut, CH; Gass, ML; Hamdy, RC; Holick, MF; Leib, ES; Lewiecki, ME; Maricic, M; Watts, NB	1
Gold, DT; Silverman, SL	1
Deswaef, A; Fabri, V; Mertens, R; Rabenda, V; Reginster, JY; Sumkay, F; Vannecke, C; Vanoverloop, J; Verpooten, GA	1
Gärtner, R	1
Col, NF; Eckman, MH; Goldberg, RJ; Orr, RK; Pauker, SG; Ross, EM; Wong, JB	1
Body, JJ; Sternon, J	1
Compston, JE	1

Reviews

9 review(s) available for raloxifene hydrochloride and Hip Fractures

Article	Year
[Drug selection guide for osteoporosis determined by the clinical staging, pathophysiology and age]. Nihon rinsho. Japanese journal of clinical medicine, 2009, Volume: 67, Issue:5 Topics: Age Factors; Bone Density; Bone Density Conservation Agents; Bone Remodeling; Bone Resorption; Calcium; Diphosphonates; Drug Therapy, Combination; Female; Hip Fractures; Humans; Osteoporosis; Raloxifene Hydrochloride; Risk; Vitamin D	2009
[Bone quality]. Nihon rinsho. Japanese journal of clinical medicine, 2009, Volume: 67, Issue:5 Topics: Absorptiometry, Photon; Alendronate; Bone and Bones; Bone Density Conservation Agents; Clinical Trials as Topic; Diagnostic Imaging; Diphosphonates; Hip Fractures; Humans; Osteoporosis; Raloxifene Hydrochloride; Risk Assessment	2009
[Diagnostic imaging of treatment in osteoporosis: SERM]. Clinical calcium, 2011, Volume: 21, Issue:7 Topics: Absorptiometry, Photon; Bone and Bones; Bone Density; Female; Hip Fractures; Humans; Indoles; Osteoporosis; Raloxifene Hydrochloride; Risk; Selective Estrogen Receptor Modulators; Spinal Fractures; Tomography, X-Ray Computed	2011
[Osteoporosis: prevention of bone loss and fractures]. MMW Fortschritte der Medizin, 2002, Nov-28, Volume: 144, Issue:48 Topics: Absorptiometry, Photon; Aged; Aged, 80 and over; Alendronate; Bone Diseases, Metabolic; Diagnosis, Differential; Exercise; Female; Fractures, Bone; Hip Fractures; Humans; Male; Middle Aged; Osteoporosis; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Risk Factors; Spinal Fractures; Time Factors; Tomography, X-Ray Computed	2002
[Which is the better choice, estrogen or SERMs in postmenopausal women?]. Clinical calcium, 2004, Volume: 14, Issue:10 Topics: Breast Neoplasms; Estrogen Replacement Therapy; Female; Hip Fractures; Hot Flashes; Humans; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Risk; Selective Estrogen Receptor Modulators; Spinal Fractures; Uterine Hemorrhage	2004
Skeletal and nonskeletal effects of raloxifene. Current osteoporosis reports, 2003, Volume: 1, Issue:3 Topics: Aged; Breast Neoplasms; Cardiovascular Diseases; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fractures, Spontaneous; Hip Fractures; Humans; Middle Aged; Osteoporosis, Postmenopausal; Prognosis; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Risk Factors; Selective Estrogen Receptor Modulators; Severity of Illness Index; Spinal Fractures; Treatment Outcome	2003
A rational approach to evidence gaps in the management of osteoporosis. The American journal of medicine, 2005, Volume: 118, Issue:11 Topics: Age Factors; Aged; Animals; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Bone Resorption; Case Management; Cohort Studies; Diphosphonates; Drug Therapy, Combination; Estrogens; Evidence-Based Medicine; Female; Follow-Up Studies; Fractures, Spontaneous; Health Surveys; Hip Fractures; Humans; Incidence; Middle Aged; Osteoporosis, Postmenopausal; Parathyroid Hormone; Raloxifene Hydrochloride; Rats; Risk Assessment; Spinal Fractures; Time Factors	2005
Review of treatment modalities for postmenopausal osteoporosis. Southern medical journal, 2005, Volume: 98, Issue:10 Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Calcium; Combined Modality Therapy; Diet; Dietary Supplements; Diphosphonates; Etidronic Acid; Exercise; Female; Fish Oils; Hip Fractures; Humans; Ibandronic Acid; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Risedronic Acid; Teriparatide; Vitamin D; Vitamin D Deficiency	2005
[Osteoporosis in the elderly--diagnosis and treatment]. MMW Fortschritte der Medizin, 2005, Feb-17, Volume: 147, Issue:7 Topics: Accidental Falls; Age Factors; Aged, 80 and over; Bone Density; Bone Density Conservation Agents; Calcium; Diphosphonates; Etidronic Acid; Exercise; Female; Hip Fractures; Humans; Male; Osteoporosis; Osteoporosis, Postmenopausal; Practice Guidelines as Topic; Raloxifene Hydrochloride; Risedronic Acid; Risk Factors; Sex Factors; Spinal Fractures; Vitamin D	2005

Trials

1 trial(s) available for raloxifene hydrochloride and Hip Fractures

Article	Year
Risk-benefit profile for raloxifene: 4-year data From the Multiple Outcomes of Raloxifene Evaluation (MORE) randomized trial. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 2004, Volume: 19, Issue:8 Topics: Aged; Breast Neoplasms; Coronary Disease; Double-Blind Method; Female; Hip Fractures; Humans; Middle Aged; Osteoporosis, Postmenopausal; Proportional Hazards Models; Pulmonary Embolism; Raloxifene Hydrochloride; Risk Assessment; Stroke; Treatment Outcome	2004

Article

Year

Risk-benefit profile for raloxifene: 4-year data From the Multiple Outcomes of Raloxifene Evaluation (MORE) randomized trial.

Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 2004, Volume: 19, Issue:8

Topics: Aged; Breast Neoplasms; Coronary Disease; Double-Blind Method; Female; Hip Fractures; Humans; Middle Aged; Osteoporosis, Postmenopausal; Proportional Hazards Models; Pulmonary Embolism; Raloxifene Hydrochloride; Risk Assessment; Stroke; Treatment Outcome

2004

Other Studies

20 other study(ies) available for raloxifene hydrochloride and Hip Fractures

Article	Year
Effectiveness of antiresorptive medications in women on long-term dialysis after hip fracture: A population-based cohort study. PloS one, 2020, Volume: 15, Issue:9 Topics: Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Female; Follow-Up Studies; Hip Fractures; Humans; Incidence; Longitudinal Studies; Middle Aged; Prognosis; Raloxifene Hydrochloride; Renal Dialysis; Retrospective Studies; Survival Rate; Taiwan	2020
Individualizing osteoporosis medications. Menopause (New York, N.Y.), 2014, Volume: 21, Issue:3 Topics: Absorptiometry, Photon; Administration, Intranasal; Aged; Antibodies, Monoclonal, Humanized; Bone Density; Bone Density Conservation Agents; Calcitonin; Calcium, Dietary; Denosumab; Diphosphonates; Female; Hip Fractures; Hot Flashes; Humans; Middle Aged; Osteoporosis, Postmenopausal; Osteoporotic Fractures; Precision Medicine; Raloxifene Hydrochloride; Risk Factors; Vitamin D	2014
Evaluation of the prescription of osteoporosis treatment after a major osteoporotic fracture. Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases, 2014, Volume: 20, Issue:6 Topics: Aged; Aged, 80 and over; Bone Density Conservation Agents; Calcium; Dietary Supplements; Diphosphonates; Female; Follow-Up Studies; Fractures, Bone; France; Hip Fractures; Humans; Imidazoles; Male; Middle Aged; Osteoporosis; Osteoporotic Fractures; Prescriptions; Raloxifene Hydrochloride; Retrospective Studies; Thiophenes; Treatment Outcome; Vitamin D; Wrist Injuries; Zoledronic Acid	2014
Efficacy, effectiveness and side effects of medications used to prevent fractures. Journal of internal medicine, 2015, Volume: 277, Issue:6 Topics: Alendronate; Antibodies, Monoclonal, Humanized; Bone Density Conservation Agents; Calcium Compounds; Denosumab; Diphosphonates; Etidronic Acid; Evidence-Based Medicine; Hip Fractures; Humans; Ibandronic Acid; Imidazoles; Osteoporosis; Osteoporotic Fractures; Raloxifene Hydrochloride; Risedronic Acid; Risk Assessment; Spinal Fractures; Teriparatide; Thiophenes; Treatment Outcome; Vitamin D; Zoledronic Acid	2015
Initiation of anti-osteoporotic therapy in patients with recent fractures: a nationwide analysis of prescription rates and persistence. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2009, Volume: 20, Issue:2 Topics: Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Drug Administration Schedule; Drug Prescriptions; Female; Fractures, Bone; Hip Fractures; Humans; Male; Middle Aged; Patient Compliance; Practice Patterns, Physicians'; Raloxifene Hydrochloride; Sex Distribution; Spinal Fractures; Treatment Outcome	2009
Adherence to osteoporosis drugs and fracture prevention: no evidence of healthy adherer bias in a frail cohort of seniors. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2011, Volume: 22, Issue:3 Topics: Aged; Aged, 80 and over; Bone Density Conservation Agents; Calcitonin; Diphosphonates; Female; Frail Elderly; Hip Fractures; Humans; Humerus; Osteoporosis, Postmenopausal; Osteoporotic Fractures; Patient Compliance; Pennsylvania; Radius Fractures; Raloxifene Hydrochloride; Ulna Fractures	2011
Fracture risk in early postmenopausal women assessed using FRAX. Joint bone spine, 2010, Volume: 77, Issue:4 Topics: Absorptiometry, Photon; Bone Density; Bone Density Conservation Agents; Diphosphonates; Estrogen Replacement Therapy; Female; Fractures, Bone; France; Hip Fractures; Humans; Middle Aged; Models, Statistical; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Risk Factors	2010
Risk of femoral shaft and subtrochanteric fractures among users of bisphosphonates and raloxifene. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2011, Volume: 22, Issue:3 Topics: Aged; Aged, 80 and over; Bone Density Conservation Agents; Case-Control Studies; Denmark; Diphosphonates; Female; Femoral Fractures; Hip Fractures; Humans; Male; Middle Aged; Organometallic Compounds; Osteoporosis; Raloxifene Hydrochloride; Risk Factors; Thiophenes	2011
Longitudinal change in hip fracture incidence after starting risedronate or raloxifene: an observational study. Journal of bone and mineral metabolism, 2011, Volume: 29, Issue:5 Topics: Aged; Aged, 80 and over; Bone Density Conservation Agents; Case-Control Studies; Etidronic Acid; Female; Hip Fractures; Humans; Longitudinal Studies; Raloxifene Hydrochloride; Risedronic Acid	2011
Treatment of osteoporosis and hip fractures in a Spanish health area. European review for medical and pharmacological sciences, 2013, Volume: 17, Issue:2 Topics: Bone Density Conservation Agents; Diphosphonates; Hip Fractures; Humans; Longitudinal Studies; Organometallic Compounds; Osteoporosis; Raloxifene Hydrochloride; Retrospective Studies; Spain; Thiophenes	2013
Improvement in the undertreatment of osteoporosis following hip fracture. The Journal of bone and joint surgery. American volume, 2002, Volume: 84, Issue:8 Topics: Aged; Aged, 80 and over; Calcitonin; Calcium; Female; Femoral Neck Fractures; Hip Fractures; Humans; Male; Middle Aged; Osteoporosis; Osteoporosis, Postmenopausal; Practice Patterns, Physicians'; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; United States	2002
Hip fracture patients are not treated for osteoporosis: a call to action. Arthritis and rheumatism, 2002, Dec-15, Volume: 47, Issue:6 Topics: Absorptiometry, Photon; Alendronate; Calcitonin; Calcium; Estrogen Antagonists; Estrogens; Hip Fractures; Humans; Osteoporosis; Raloxifene Hydrochloride; Retrospective Studies; Risk Factors; Treatment Failure; Vitamin D	2002
Comparison of fracture, cardiovascular event, and breast cancer rates at 3 years in postmenopausal women with osteoporosis. Journal of the American Geriatrics Society, 2004, Volume: 52, Issue:9 Topics: Age Distribution; Aged; Bone Density; Breast Neoplasms; Calcium; Cardiovascular Diseases; Female; Global Health; Hip Fractures; Humans; Incidence; Multicenter Studies as Topic; Osteoporosis, Postmenopausal; Patient Selection; Population Surveillance; Prevalence; Prospective Studies; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Risk Factors; Selective Estrogen Receptor Modulators; Spinal Fractures; Vitamin D	2004
Health-economic comparison of three recommended drugs for the treatment of osteoporosis. International journal of clinical pharmacology research, 2004, Volume: 24, Issue:1 Topics: Aged; Aged, 80 and over; Alendronate; Bone Density; Cohort Studies; Cost-Benefit Analysis; Etidronic Acid; Female; Germany; Hip Fractures; Humans; Incidence; Insurance, Pharmaceutical Services; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Risedronic Acid	2004
[Update 2004. Osteoporosis--management--current status]. Krankenpflege Journal, 2004, Volume: 42, Issue:7-10 Topics: Aged; Aged, 80 and over; Alendronate; Calcium, Dietary; Cross-Sectional Studies; Etidronic Acid; Female; Fractures, Spontaneous; Germany; Health Surveys; Hip Fractures; Humans; Male; Middle Aged; Osteoporosis; Practice Guidelines as Topic; Raloxifene Hydrochloride; Risedronic Acid; Spinal Fractures; Vitamin D	2004
Do estrogen or selective estrogen receptor modulators improve quality of life for women with postmenopausal osteoporosis? Current osteoporosis reports, 2007, Volume: 5, Issue:1 Topics: Aged; Aged, 80 and over; Back Pain; Estrogens; Fatigue; Female; Fractures, Spontaneous; Hip Fractures; Humans; Middle Aged; Osteoporosis, Postmenopausal; Postmenopause; Prevalence; Quality of Life; Raloxifene Hydrochloride; Risk Factors; Selective Estrogen Receptor Modulators; Spinal Fractures; Tamoxifen; United States	2007
Adherence to bisphosphonates therapy and hip fracture risk in osteoporotic women. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2008, Volume: 19, Issue:6 Topics: Aged; Alendronate; Bone Density Conservation Agents; Diphosphonates; Drug Administration Schedule; Epidemiologic Methods; Female; Hip Fractures; Humans; Middle Aged; Osteoporosis, Postmenopausal; Patient Compliance; Raloxifene Hydrochloride	2008
Individualizing therapy to prevent long-term consequences of estrogen deficiency in postmenopausal women. Archives of internal medicine, 1999, Jul-12, Volume: 159, Issue:13 Topics: Alendronate; Bone Density; Breast Neoplasms; Coronary Disease; Decision Support Techniques; Estrogen Replacement Therapy; Estrogens; Estrogens, Conjugated (USP); Female; Hip Fractures; Humans; Life Expectancy; Lipids; Markov Chains; Middle Aged; Osteoporosis, Postmenopausal; Piperidines; Postmenopause; Raloxifene Hydrochloride; Risk; Risk Factors; Sensitivity and Specificity	1999
[Raloxifene (Celvista, Evista)]. Revue medicale de Bruxelles, 2000, Volume: 21, Issue:1 Topics: Arteriosclerosis; Bone and Bones; Breast Neoplasms; Controlled Clinical Trials as Topic; Endometrium; Female; Fractures, Bone; Heart Diseases; Hip Fractures; Humans; Middle Aged; Osteoporosis, Postmenopausal; Placebos; Prospective Studies; Raloxifene Hydrochloride; Risk Factors; Selective Estrogen Receptor Modulators; Spinal Fractures; Thromboembolism; Uterine Hemorrhage	2000
Pharmacological interventions for the prevention of vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: does site-specificity exist? Bone, 2000, Volume: 27, Issue:6 Topics: Aged; Alendronate; Calcitriol; Calcium Channel Agonists; Calcium Channel Blockers; Estrogen Antagonists; Etidronic Acid; Female; Hip Fractures; Humans; Middle Aged; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Risedronic Acid; Spinal Fractures	2000